Dr. Jungjoon Lee demonstrated his early interest in science when he was selected as a representative of Great Britain for the International Chemistry Olympiad, where he won a silver medal, and the International Physics Olympiad, which he declined. He received his B.A. and M.Sci. from the University of Cambridge and his Ph.D. from Stanford University. During his time at Cambridge, he worked as a UROP student in Professor David Spring’s organic chemistry lab and completed his master’s project in Professor Carol Robinson’s structural biology lab. During his Ph.D. at Stanford, he was involved in numerous directed evolution projects in Professor Jianghong Rao’s lab. In 2011, after graduating, he joined the Bio-therapeutics lab at the Samsung Advanced Institute of Technology as a senior researcher. It was during a period when Samsung, a company ranked #12 in global pharmaceutical market capitalization in 2023, actively sought to expand its biologics sector that he participated in various task forces to steer its strategic direction, a contribution recognized by the award of the Multiple Citizenship for Outstanding Talent from the Ministry of Justice, Korea—a distinction granted to about 20 notable individuals annually. Impressed by the CRISPR revolution, he moved to the Seoul National University Institute of Molecular Biology and Genetics in 2014 as the principal investigator for the joint project between Seoul National University and Toolgen, a genome editing company founded by Professor Jin-soo Kim. He later joined Toolgen as Head of Research for the platform development team in 2016. His team secured many significant patents and publications in CRISPR technology and contributed to Toolgen’s successful IPO on KOSDAQ. He is also a founding member of the Korean Association for Genome Editing, where he serves as vice chairman. In 2024, Dr. Lee joined the National University of Singapore as an assistant professor in the Department of Biochemistry and Synthetic Biology for Clinical & Technological Innovation (SynCTI).